Cargo Therapeutics completed its initial public offering and commenced trading of its common stock on the Nasdaq Global Select Market under the ticker symbol CRGX in late 2023. The offering marked a significant milestone for the clinical-stage biotechnology enterprise, allowing the firm to secure substantial capital to advance its proprietary platform of next-generation cell therapies designed to address cancer treatment resistance. Since its market debut, the company has utilized these funds to support its ongoing clinical pipelines and corporate expansion initiatives.
A high dividend yield trap occurs when a company displays an abnormally high dividend yield on paper—often resulting from a severe, sudden drop in its share price due to deteriorating business fundamentals. Unwary income-seeking investors might buy the stock attracted by the high payout ratio, only to experience heavy capital losses when the underlying corporation is eventually forced to slash or eliminate its dividend entirely to preserve cash flow. Evaluating balance sheet health, debt levels, and earnings sustainability helps investors avoid these traps.